natgillin/translations-raw huggingface dataset:
In the study of Tarceva used in combination with gemcitabine for pancreatic cancer, the most common side effects were tiredness (affecting 73% of patients), rash (69%) and diarrhoea (48%).
V študiji z zdravilom Tarceva, uporabljenim v kombinaciji z gemcitabinom za zdravljenje raka trebušne slinavke, so bili najpogostejši neželeni učinki utrujenost (pri 73 % bolnikov), izpuščaji (pri 69 % bolnikov) in driska (pri 48 % bolnikov).
• previously untreated patients whose cancer cells have certain changes (‘activating mutations') in the gene for a protein called epidermal growth factor receptor (EGFR);
• bolnikih, pri katerih se na rakavih celicah pojavijo spremembe („aktivirajoče mutacije“) v genu za beljakovino, imenovano receptor za epidermalni rastni dejavnik (EGFR), ki se predhodno še niso zdravili;
Patients with NSCLC should be tested for EGFR activating mutation before starting Tarceva, unless previous chemotherapy has not worked and other treatments are not suitable.
Pri bolnikih z nedrobnoceličnim pljučnim rakom je treba pred začetkom zdravljenja z zdravilom Tarceva opraviti teste za EGFR-aktivirajoče mutacije, razen če predhodna kemoterapija ni delovala in druga zdravljenja zanje niso primerna.
• The fourth study compared Tarceva with placebo in 731 patients in whom at least one previous chemotherapy treatment had not worked.
• V četrti študiji so zdravilo Tarceva primerjali s placebom pri 731 bolnikih, pri katerih vsaj eno predhodno zdravljenje s kemoterapijo ni bilo uspešno.
In studies, the most common side effects with Tarceva when used as monotherapy for lung cancer were rash (affecting 75% of patients), diarrhoea (54%), loss of appetite and tiredness (52% each).
V študijah so bili najpogostejši neželeni učinki zdravila Tarceva, kadar je bilo uporabljeno kot samostojno zdravilo za zdravljenje pljučnega raka, izpuščaji (pri 75 % bolnikov), driska (pri 54 % bolnikov), izguba teka in utrujenost (pri 52 % bolnikov).
For pancreatic cancer, it is 100 mg daily.
Običajni odmerek pri nedrobnoceličnem pljučnem raku je 150 mg na dan, pri raku trebušne slinavke pa 100 mg na dan.
Patients taking Tarceva survived for an average of 6.7 months, compared with 4.7 months for the patients taking placebo.
Bolniki, ki so jemali zdravilo Tarceva, so preživeli povprečno 6,7 meseca, medtem ko so bolniki, ki so jemali placebo, preživeli 4,7 meseca.
• A third study compared Tarceva with placebo in 643 patients with advanced NSCLC whose cancer cells did not have EGFR activating mutations and whose disease was stable after 4 cycles of treatment with platinum-containing chemotherapy.
• V tretji študiji so zdravilo Tarceva primerjali s placebom pri 643 bolnikih z napredovalim nedrobnoceličnim pljučnim rakom, pri katerih rakave celice niso imele EGFR-aktivirajočih mutacij in pri katerih je bila bolezen stabilna po štirih ciklih zdravljenja s kemoterapijo s platino.
• patients without EGFR activating mutations in whom previous chemotherapy has not worked and other treatments are unsuitable.
• bolnikih brez EGFR-aktivirajočih mutacij, pri katerih predhodna kemoterapija ni delovala, druga zdravljenja pa zanje niso primerna.
• The first study compared Tarceva with chemotherapy in 173 patients with advanced NSCLC with activating EGFR mutations who had not received previous chemotherapy.
• V prvi študiji so zdravilo Tarceva primerjali s kemoterapevtikom pri 173 bolnikih z napredovalim nedrobnoceličnim pljučnim rakom z EGFR-aktivirajočimi mutacijami, ki predhodno niso prejemali kemoterapije.
• patients with EGFR activating mutations in whom previous chemotherapy has not worked;
• bolnikih z EGFR-aktivirajočimi mutacijami, pri katerih predhodna kemoterapija ni delovala;
• The second study compared Tarceva with placebo (a dummy treatment) in 889 patients with advanced or metastatic NSCLC whose disease had not got worse after 4 cycles of treatment with platinum-containing chemotherapy.
• V drugi študiji so zdravilo Tarceva primerjali s placebom (zdravilom brez učinkovine) pri 889 bolnikih z napredovalim ali metastatskim nedrobnoceličnim pljučnim rakom, pri katerih se bolezen po štirih ciklih zdravljenja s kemoterapijo s platino ni poslabšala.
Patients with metastatic cancer taking Tarceva as initial therapy lived without their disease getting worse for an average of 5.9 months, compared with 5.1 months in those taking placebo.
Pri bolnikih z metastatskim rakom, ki so jemali zdravilo Tarceva kot začetno zdravljenje, je bil čas do poslabšanja bolezni v povprečju 5,9 meseca, pri bolnikih, ki so jemali placebo, pa 5,1 meseca.
However, there was no advantage for patients whose cancer had not spread beyond the pancreas.
Pri bolnikih, pri katerih se rak trebušne slinavke ni razširil, ni bilo nobene razlike z vidika časa preživetja.
Patients taking Tarceva lived for an average of 10.4 months without their disease getting worse compared with 5.1 months for those receiving chemotherapy medicines.
Bolniki, zdravljeni z zdravilom Tarceva, so brez poslabšanja bolezni živeli povprečno 10,4 meseca, bolniki, ki so se zdravili s kemoterapevtiki, pa 5,1 meseca.
Overall, Tarceva marginally increased how long patients lived without their disease getting worse and how long they survived.
Na splošno je zdravilo Tarceva nekoliko podaljšalo čas do poslabšanja bolezni in čas preživetja bolnikov.
In NSCLC, Tarceva has been mainly studied in four studies.
Zdravilo Tarceva so pri zdravljenju nedrobnoceličnega pljučnega raka večinoma proučevali v štirih študijah.
How does Tarceva work?
Kako zdravilo Tarceva deluje?
The usual dose is one tablet each day.
Običajen odmerek je 1 tableta vsak dan.
≥ 1/100 and < 1/10
≥ 1/100 in < 1/10
They are used together when treatment with just one is insufficient.
Skupaj se uporabljata, če zdravljenje s samo eno od njiju ni bilo zadostno.
Italy, Portugal: Inibace Plus
Italija, Portugalska: Inibace Plus
The combination is effective irrespective of age, gender and race.
Kombinacija je učinkovita ne glede na starost, spol in raso.
Safety and efficacy in children and adolescents below 18 years of age have not been established.
Varnost in učinkovitost pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
Cough is more common in women and nonsmokers.
Kašelj je pogostejši pri ženskah in nekadilcih.
- if you have porphyria.
- če imate porfirijo.
Plasma protein binding is approximately 25 to 30%.
Vezava na plazemske beljakovine znaša približno 25 do 30 %.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines: - Any medicines used to treat high blood pressure.
Še zlasti morate zdravniku ali farmacevtu povedati, če jemljete katero od naslednjih zdravil: - kakršnakoli zdravila za zdravljenje visokega krvnega tlaka.
It also makes it easier for your heart to pump blood around your body.
Poleg tega srcu tudi olajša črpanje krvi po telesu.
- Cyclosporine (used to stop the rejection of organs after transplantation).
- ciklosporin (uporablja se za preprečevanje zavrnitve organov po presaditvi).
The tablets must not be chewed or crushed and should always be swallowed with a drink of water.
Tablet se ne sme žvečiti ali drobiti in se jih mora vedno zaužiti z nekaj vode.
Clinical/Efficacy Studies
Klinične študije/študije učinkovitosti
The category `uncommon' incorporates `rare' (≥1/10'000 and <1/1'000) and `very rare' (<1/10'000), which may be used in some SPCs for other products.
Kategorija "občasni" vključuje kategoriji "redki" (≥ 1/10.000 in < 1/1.000) in "zelo redki" (< 1/10.000), ki sta lahko uporabljeni v povzetkih glavnih značilnosti drugih zdravil.
(It is also better to avoid Vascace Plus in early pregnancy - see the sections on “Pregnancy” and “Breastfeeding”.)
(Bolje je tudi, če se zdravilu Vascace Plus v zgodnji nosečnosti izogibate - glejte poglavji "Nosečnost" in "Dojenje".)
Austria: Inhibace Plus “Roche” Belgium, Luxembourg: Co-Inhibace Cyprus, Greece: Vascace Plus Czech Republic, Hungary, Poland, Spain: Inhibace Plus Germany: Dynorm Plus
Avstrija: Inhibace Plus „Roche“ Belgija, Luksemburg: Co-Inhibace Ciper, Grčija: Vascace Plus Češka, Madžarska, Poljska, Španija: Inhibace Plus Nemčija: Dynorm Plus
Very common ≥ 1/10 Common
zelo pogosti ≥ 1/10 pogosti
Vascace Plus is not suitable for people with certain types of heart problem.
Zdravilo Vascace Plus ni primerno za osebe z določenimi vrstami težav s srcem.
Pharmacokinetics in Special Populations
Farmakokinetika v posebnih populacijah
Taking this medicine - Swallow each tablet with a drink of water.
Jemanje tega zdravila - Tableto pogoltnite z nekaj vode.
Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded.
Epidemiološki podatki glede tveganja za teratogenost po izpostavljenosti zaviralcem ACE v prvem tromesečju nosečnosti niso dokončni; vendar pa majhnega povečanja tveganja ni mogoče izključiti.
This indicates that there is an influence on rate but not on the extent of absorption of both medicines.
da obstaja vpliv na hitrost, vendar ne na obseg absorpcije obeh zdravilnih očinkovin.
Reasons may include (i) differences between the target populations treated with Vascace Plus and Vascace, (ii) differences in cilazapril dose, and (iii) specific effects of combination therapy.
Razlogi so lahko naslednji: (i) razlike med ciljnimi populacijami, ki so jih zdravili z zdraviloma Vascace Plus in Vascace, (ii) razlike v odmerku cilazaprila in (iii) specifični učinki kombiniranega zdravljenja.
ANNEX III SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
PRILOGA III POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJE IN NAVODILO ZA UPORABO
Use in children and adolescents Vascace Plus is not recommended for use in children and adolescents below 18 years of age.
Uporaba pri otrocih in mladostnikih Zdravila Vascace Plus ni priporočljivo uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
The mean lethal doses in rats, mice, and cynomolgus monkeys were higher than 2000 mg/kg body weight.
Povprečne letalne doze pri podganah, miših in opicah cynomolgus so bile večje od 2.000 mg/kg telesne mase.
Vascace Plus is used to treat high blood pressure.
Zdravilo Vascace Plus se uporablja za zdravljenje visokega krvnega tlaka.
Hydrochlorothiazide should not be used for the treatment of essential hypertension in pregnant women except in rare situations where no other therapy can be used.
Hidroklorotiazida se ne sme uporabljati za zdravljenje esencialne hipertenzije pri nosečnicah, razen v tistih redkih primerih, ko ni mogoče uporabiti nobenega drugega zdravila.
- Iodine containing contrast media (given to patients before certain types of X-ray examination).
- kontrastna sredstva, ki vsebujejo jod (ki jih bolniki dobijo pred določenimi rentgenskimi preiskavami).
- If you have severe kidney problems (creatinine clearance less than 30 ml/min) or anuria (inability to pass urine).
- če imate hude težave z ledvicami (očistek kreatinina manjši od 30 ml/min) ali anurijo (ste nezmožni odvajati urin).
Estimates of frequency are based on the proportion of patients reporting each adverse reaction during Vascace Plus clinical trials that included a total combined population of 1'097 patients.
Ocene pogostnosti temeljijo na deležu bolnikov, pri katerih se je pojavil posamezen neželen učinek med kliničnimi preskušanji z zdravilom Vascace Plus, ki so v celoti zajela kombinirano populacijo 1.097 bolnikov.
Non-depolarizing muscle relaxants
Nedepolarizirajoči mišični relaksanti
Reductions in maternal blood volume could also adversely affect placental perfusion.
Zmanjšanje volumna krvi pri materi ima lahko tudi škodljiv vpliv na placentno perfuzijo.
Important information about some of the ingredients of Vascace Plus Vascace Plus contains lactose, which is a type of sugar.
Pomembne informacije o nekaterih sestavinah zdravila Vascace Plus Zdravilo Vascace Plus vsebujejo laktozo, ki je vrsta sladkorja.
In patients not responding to 5 mg cilazapril given as monotherapy, the addition of hydrochlorothiazide at a low dose of 12.5 mg once daily substantially improves the response to treatment.
Pri bolnikih, ki se ne odzivajo na monoterapijo s 5 mg cilazaprila na dan, dodatek hidroklorotiazida v nizkem odmerku 12,5 mg enkrat na dan znatno izboljša odziv na zdravljenje.
If you forget to take Vascace Plus - If you forget to take a dose, skip the missed dose.
Če ste pozabili vzeti zdravilo Vascace Plus - Če pozabite vzeti odmerek, pozabljeni odmerek preskočite.
For cilazaprilat, the volume of distribution has been determined to be approximately 0.5 to 0.7 l/kg.
Za cilazaprilat je volumen porazdelitve približno 0,5 do 0,7 l/kg.
Tell your doctor or pharmacist if you are taking food supplements that contain potassium.
Zdravniku ali farmacevtu morate povedati, če uporabljate prehranske dodatke, ki vsebujejo kalij.
Hydrochlorothiazide binds to 65% to plasma proteins; the relative volume of distribution has been determined to be 0.5 to 1.1 l/kg.
Hidroklorotiazid se v 65 % veže na plazemske beljakovine; relativni volumen porazdelitve je približno 0,5 do 1,1 l/kg
Do not use Vascace Plus after the expiry date which is stated on the pack after EXP.
Zdravila Vascace Plus ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pakiranju poleg oznake EXP.
They occurred only at 50 mg/kg corresponding to high multiples of therapeutic human doses.
Do tega je prišlo pri odmerkih 50 mg/kg, kar je visok večkratnik terapevtskih odmerkov pri ljudeh.
Studies on the effect on peri- and postnatal performance and on fertility were not conducted with the combination.
Vpliv na plodnost Študij o vplivu na peri- in postnatalno obdobje ter na plodnost z zadevno kombinacijo niso izvedli.
Do not take Vascace Plus if any of the above apply to you.
Ne vzemite zdravila Vascace Plus, če kaj od naštetega velja za vas.
It delays hydrochlorothiazide Tmax by 1.4 hours and reduces Cmax by 14% with no effect on overall bioavailability of both molecules as assessed by AUC0-24-value.
Pri hidroklorotiazidu pa upočasni Tmax za 1,4 ure in zmanjša Cmax za 14 %, brez vpliva celokupno biološko uporabnost obeh molekul, kot je bilo ocenjeno z vrednostmi AUC
These changes were demonstrated to be reversible and are a consequence of exaggerated pharmacodynamic activity of cilazapril occurring only at high multiples of the therapeutic human doses.
Te spremembe so bile reverzibilne in so posledica pretirane farmakodinamske aktivnosti cilazaprila, do katere pride le pri uporabi visokih večkratnikov terapevtskih odmerkov pri človeku.
Do not take Vascace Plus - if you are allergic (hypersensitive) to cilazapril, hydrochlorothiazide or any of the other ingredients of Vascace Plus (listed in section 6: Further information).
Ne jemljite zdravila Vascace Plus - če ste alergični (preobčutljivi) na cilazapril, hidroklorotiazid ali katerokoli sestavino zdravila Vascace Plus (glejte poglavje 6: Dodatne informacije).
Your doctor will normally advise you to stop taking Vascace Plus before you become pregnant, or as soon as you know you are pregnant, and will advise you to take another medicine instead of Vascace Plus.
Zdravnik vam bo praviloma svetoval, da nehajte jemati zdravilo Vascace Plus, preden zanosite, ali čim ugotovite, da ste noseči, in vam bo namesto zdravila Vascace Plus svetoval drugo zdravilo.
Non-depolarizing muscle relaxants should not be administered simultaneously, due to possible intensification and prolongation of the muscular relaxing effect.
Nedepolarizirajočih mišičnih relaksantov se ne sme uporabljati sočasno, saj lahko pride do povečanja in podaljšanja relaksantnega učinka na mišice.
When driving and operating machines, it should be taken into account that occasionally dizziness and fatigue may occur during treatment with Vascace Plus (see sections 4.4 and 4.8).
V primeru vožnje in upravljanja s stroji je treba upoštevati, da se med zdravljenjem z zdravilom Vascace Plus lahko občasno pojavita omotica in utrujenost (glejte poglavji 4.4 in 4.8).
In clinical studies, the efficacy and tolerability of cilazapril and hydrochlorothiazide administered concomitantly was similar in both elderly and younger hypertensive patients, although pharmacokinetic data show that clearance of both components in elderly patients was reduced (see section 5.2).
V kliničnih študijah sta bili učinkovitost in prenašanje kombinacije cilazaprila s hidroklorotiazidom podobni pri starejših in pri mlajših bolnikih s hipertenzijo, čeprav farmakokinetični podatki kažejo, da je očistek obeh učinkovin pri starejših zmanjšan (glejte poglavje 5.2).
It works by increasing the amount of water (urine) you produce.
Deluje tako, da poveča nastajanje seča (urina).
In elderly patients whose renal function is normal for age, plasma concentrations of cilazaprilat may be up to 40% higher, and clearance 20% lower, than in younger patients.
Pri starejših bolnikih, ki imajo glede na starost normalno delovanje ledvic, je lahko koncentracija cilazaprilata v plazmi do 40 % večja, očistek pa 20 % manjši kot pri mlajših bolnikih.
Hydrochlorothiazide is eliminated largely unchanged by the kidney, with a half-life of 7 to 11 hours.
Hidroklorotiazid se izloča večinoma nespremenjen skozi ledvice, njegov razpolovni čas je 7 do 11 ur.
Vascace Plus is contraindicated in patients with creatinine clearance <30 ml/min/1.73 m2.
Zdravilo Vascace Plus je kontraindicirano pri bolnikih z očistkom kreatinina < 30 ml/min/1,73 m2.
The recommended treatment of Vascace Plus overdosage is intravenous infusion of sodium chloride 9 mg/ml (0.9%) solution.
Priporočeno zdravljenje prevelikega odmerjanja zdravila Vascace Plus je intravensko infundiranje 9 mg/ml (0,9 %) raztopine natrijevega klorida.
Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly patients compared to young healthy volunteers.
Podatki, ki jih je malo, kažejo, da je sistemski očistek hidroklorotiazida tako pri zdravih kot pri hipertenzivnih starejših bolnikih manjši od tistega pri mladih zdravih prostovoljcih.
Vascace Plus is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Uporaba zdravila Vascace Plus v zgodnji nosečnosti ni priporočljiva, ne smete pa ga jemati, če ste noseči dlje kot 3 mesece, ker lahko resno škoduje otroku, če se ga uporablja po tretjem mesecu nosečnosti.
The combination at various doses produces greater blood pressure reduction than either of the two individual components.
Kombinacija učinkovin v različnih odmerkih je povzročila večje znižanje krvnega tlaka kot uporaba katerekoli od posameznih učinkovin.
- if you have had a stroke or have problems with the blood supply to your brain.
- če ste kdaj imeli možgansko kap ali imate težave s prekrvavitvijo možganov.
As with other ACE inhibitors, signs of foetotoxicity were observed in rats.
Kot pri drugih zaviralcih ACE so pri podganah opazili znake fetotoksičnosti.
Vascace Plus should be used with caution in patients with porphyria.
Zdravilo Vascace Plus je treba uporabljati previdno pri bolnikih s porfirijo.
Pharmacotherapeutic group: Antihypertensive; ACE inhibitor and diuretic, ATC code: C09BA08
Farmakoterapevtska skupina: antihipertenzivi; zaviralci angiotenzinske konvertaze in diuretiki; oznaka ATC: C09BA08
The main findings were increased pre-implantation loss and fewer viable foetuses.
Glavni opažanji sta bili povečano število predimplantacijskih izgub in manj donošenih plodov.
Maximum plasma concentrations are achieved within 2 hours post dosing.
Največja koncentracija v plazmi je dosežena v 2 urah po zaužitju.
Subchronic and chronic toxicity studies with hydro-chlorothiazide in rats and dogs showed no noticeable findings except for changes in the electrolyte balance (hypokalaemia).
V študijah subkronične ter kronične toksičnosti s hidroklorotiazidom pri podganah in psih ni bilo pomembnih izsledkov, razen sprememb v ravnotežju elektrolitov (hipokaliemija).
No tests of carcinogenicity were conducted with the combination.
Študij kancerogenosti z zadevno kombinacijo niso izvedli.
WHAT VASCACE PLUS IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO VASCACE PLUS IN ZA KAJ GA UPORABLJAMO
The acute oral toxicity of cilazapril is low.
Akutna peroralna toksičnost cilazaprila je majhna.
Studies performed with Vascace Plus have demonstrated that the combination of cilazapril and hydrochlorothiazide administered once daily at various doses reduces systolic and diastolic blood pressure compared to placebo 24 hours after dosing, to an extent that is both statistically significant and clinically meaningful.
Študije z zdravilom Vascace Plus so pokazale, da jemanje kombinacije cilazaprila in hidroklorotiazida enkrat na dan v različnih odmerkih zniža sistolični in diastolični krvni tlak v primerjavi s placebom; učinek se v statistično značilni in klinično pomembni meri ohrani 24 ur po odmerjanju.
There is limited experience with hydrochlorothiazide during pregnancy.
Izkušenj s hidroklorotiazidom med nosečnostjo je malo.
This is because Vascace Plus can affect the way some medicines work.
Zdravilo Vascace Plus namreč lahko vpliva na delovanje nekaterih zdravil.
Taking Vascace Plus with food and drink Vascace Plus my be taken with or without food.
Jemanje zdravila Vascace Plus skupaj s hrano in pijačo Zdravilo Vascace Plus lahko vzamete s hrano ali brez nje.
Vascace Plus is indicated for the treatment of hypertension in adult patients whose blood pressure is not adequately controlled with cilazapril alone.
Zdravilo Vascace Plus je indicirano za zdravljenje hipertenzije pri odraslih bolnikih, pri katerih krvni tlak ni ustrezno urejen samo s cilazaprilom.
If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered.
V poštev pride tudi zdravljenje z infuzijo angiotenzina II in/ali intravenska uporaba kateholaminov, če je na voljo.
The dose of Vascace Plus is one tablet (5.0 mg cilazapril and 12.5 mg hydrochlorothiazide) administered once daily.
Odmerek zdravila Vascace Plus je ena tableta (5,0 mg cilazaprila in 12,5 mg hidroklorotiazida) enkrat na dan.
- Do not crush or chew the tablets
- Tablet ne drobite ali žvečite.
Hydrochlorothiazide belongs to a group of medicines called ‘thiazide diuretics' or ‘water tablets'.
Hidroklorotiazid spada v skupino zdravil, imenovanih "tiazidni diuretiki" ali "tablete za odvajanje vode".
- Vascace Plus may be taken before or after a meal.
- Zdravilo Vascace Plus lahko vzamete pred obrokom ali po njem.
Also some medicines can affect the way Vascace Plus works.
Tudi nekatera zdravila lahko vplivajo na delovanje zdravila Vascace Plus.
6.2 Incompatibilities [To be completed nationally]
6.2 Inkompatibilnosti [Izpolni država članica.]
- Steroid medicines (such as hydrocortisone, prednisolone and dexamethasone) or other medication which suppress the immune system.
- steroidna zdravila (npr. hidrokortizon, prednizolon in deksametazon), ali druga zdravila, ki zavirajo imunski sistem.
The following effects may happen: feeling dizzy or light-headed, shallow breathing, cold clammy skin, being unable to move or speak and a slow or irregular heart beat.
Pojavijo se lahko naslednji učinki: omotica ali vrtoglavica, plitvo dihanje, hladna, lepljiva koža, nezmožnost gibanja ali govorjenja in počasno bitje srca.
What Vascace Plus is and what it is used for Before you take Vascace Plus How to take Vascace Plus Possible side effects
Kaj je zdravilo Vascace Plus in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Vascace Plus Kako jemati zdravilo Vascace Plus Možni neželeni učinki
- Anticholinergics.
- antiholinergike.
Thiazides may also cause hyponatraemia and dehydration.
Tiazidi lahko povzročijo tudi hiponatriemijo in dehidracijo.
Vascace Plus is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see the sections on ‘Pregnancy' and ‘Breastfeeding').
Uporaba zdravila Vascace Plus v zgodnji nosečnosti ni priporočljiva, ne smete pa ga jemati, če ste noseči dlje kot 3 mesece, ker lahko v tej fazi nosečnosti resno škoduje otroku (glejte poglavji "Nosečnost" in "Dojenje").